Oxurion NV (OXUR.BR)
EUR 0.27
(0.0%)
EUR 0.27
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -12.11 Million EUR | 46.84% |
| 2022 | -22.77 Million EUR | 20.6% |
| 2021 | -28.68 Million EUR | 3.59% |
| 2020 | -29.75 Million EUR | 21.5% |
| 2019 | -37.9 Million EUR | 3.4% |
| 2018 | -39.24 Million EUR | -33.12% |
| 2017 | -29.47 Million EUR | 13.92% |
| 2016 | -34.24 Million EUR | 12.0% |
| 2015 | -38.91 Million EUR | 26.17% |
| 2014 | -52.71 Million EUR | -306.63% |
| 2013 | 25.51 Million EUR | -12.34% |
| 2012 | 29.1 Million EUR | 217.48% |
| 2011 | -24.77 Million EUR | -268.98% |
| 2010 | 14.66 Million EUR | -2.18% |
| 2009 | 14.98 Million EUR | 41.56% |
| 2008 | 10.58 Million EUR | -39.21% |
| 2007 | 17.41 Million EUR | 67.05% |
| 2006 | 10.42 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.31 Million EUR | 0.0% |
| 2023 Q2 | -7.88 Million EUR | 0.0% |
| 2023 Q4 | -5.05 Million EUR | 0.0% |
| 2023 FY | -12.11 Million EUR | 46.84% |
| 2022 FY | -22.77 Million EUR | 20.6% |
| 2022 Q2 | -13.74 Million EUR | 0.0% |
| 2022 Q4 | -9.03 Million EUR | 0.0% |
| 2021 Q2 | -15.4 Million EUR | 0.0% |
| 2021 Q4 | -13.2 Million EUR | 0.0% |
| 2021 FY | -28.68 Million EUR | 3.59% |
| 2020 FY | -29.75 Million EUR | 21.5% |
| 2020 Q4 | -15.78 Million EUR | 0.0% |
| 2020 Q2 | -13.48 Million EUR | 0.0% |
| 2019 Q2 | -18.19 Million EUR | 0.0% |
| 2019 Q4 | -19.1 Million EUR | 0.0% |
| 2019 FY | -37.9 Million EUR | 3.4% |
| 2018 Q2 | -15.66 Million EUR | 0.0% |
| 2018 Q4 | -23.57 Million EUR | 0.0% |
| 2018 FY | -39.24 Million EUR | -33.12% |
| 2017 Q4 | -14.46 Million EUR | 0.0% |
| 2017 FY | -29.47 Million EUR | 13.92% |
| 2017 Q2 | -15.01 Million EUR | 0.0% |
| 2016 Q4 | -19.26 Million EUR | 0.0% |
| 2016 Q2 | -14.98 Million EUR | 0.0% |
| 2016 FY | -34.24 Million EUR | 12.0% |
| 2015 FY | -38.91 Million EUR | 26.17% |
| 2015 Q4 | -19.12 Million EUR | 0.0% |
| 2015 Q2 | -19.78 Million EUR | 0.0% |
| 2014 Q4 | -28.3 Million EUR | 0.0% |
| 2014 Q2 | -24.41 Million EUR | 0.0% |
| 2014 FY | -52.71 Million EUR | -306.63% |
| 2013 Q2 | 54.07 Million EUR | 0.0% |
| 2013 Q4 | -28.56 Million EUR | 0.0% |
| 2013 FY | 25.51 Million EUR | -12.34% |
| 2012 Q1 | 7.61 Million EUR | 0.0% |
| 2012 FY | 29.1 Million EUR | 217.48% |
| 2012 Q4 | 6.61 Million EUR | -13.25% |
| 2012 Q2 | 7.61 Million EUR | 0.0% |
| 2012 Q3 | 7.61 Million EUR | 0.0% |
| 2011 Q4 | 7.61 Million EUR | 240.86% |
| 2011 Q1 | -5.4 Million EUR | 0.0% |
| 2011 Q2 | -5.4 Million EUR | 0.0% |
| 2011 FY | -24.77 Million EUR | -268.98% |
| 2011 Q3 | -5.4 Million EUR | 0.0% |
| 2010 FY | 14.66 Million EUR | -2.18% |
| 2010 Q2 | -3.42 Million EUR | 0.0% |
| 2010 Q1 | -3.42 Million EUR | 0.0% |
| 2010 Q3 | -3.42 Million EUR | 0.0% |
| 2010 Q4 | -5.4 Million EUR | -57.77% |
| 2009 Q1 | -3.41 Million EUR | 0.0% |
| 2009 FY | 14.98 Million EUR | 41.56% |
| 2009 Q3 | -3.41 Million EUR | 0.0% |
| 2009 Q2 | -3.41 Million EUR | 0.0% |
| 2009 Q4 | -3.42 Million EUR | -0.39% |
| 2008 Q4 | -3.41 Million EUR | -210.73% |
| 2008 FY | 10.58 Million EUR | -39.21% |
| 2008 Q1 | 3.08 Million EUR | 0.0% |
| 2008 Q2 | 3.08 Million EUR | 0.0% |
| 2008 Q3 | 3.08 Million EUR | 0.0% |
| 2007 Q3 | -4.35 Million EUR | 0.0% |
| 2007 Q4 | 3.08 Million EUR | 170.83% |
| 2007 FY | 17.41 Million EUR | 67.05% |
| 2007 Q2 | -4.35 Million EUR | 0.0% |
| 2007 Q1 | -4.35 Million EUR | 0.0% |
| 2006 Q4 | -4.35 Million EUR | -72.04% |
| 2006 FY | 10.42 Million EUR | 0.0% |
| 2006 Q3 | -2.53 Million EUR | 0.0% |
| 2006 Q2 | -2.53 Million EUR | 0.0% |
| 2006 Q1 | -2.53 Million EUR | 0.0% |
| 2005 Q4 | -2.53 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -254.924% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 90.493% |
| Adocia SA | -17.62 Million EUR | 31.279% |
| Aelis Farma SA | -6.46 Million EUR | -87.432% |
| Biophytis S.A. | -14.33 Million EUR | 15.51% |
| Advicenne S.A. | -6.45 Million EUR | -87.548% |
| genOway Société anonyme | 2.06 Million EUR | 686.357% |
| IntegraGen SA | -183.77 Thousand EUR | -6489.759% |
| Medesis Pharma S.A. | -4.22 Million EUR | -186.333% |
| Neovacs S.A. | -6.9 Million EUR | -75.315% |
| NFL Biosciences SA | -4.43 Million EUR | -173.338% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -1456.081% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -286.006% |
| Sensorion SA | -22.31 Million EUR | 45.721% |
| Theranexus Société Anonyme | -7.64 Million EUR | -58.432% |
| TME Pharma N.V. | -5.62 Million EUR | -115.327% |
| Valbiotis SA | -7.16 Million EUR | -69.134% |
| TheraVet SA | -2.17 Million EUR | -456.754% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 40.31% |
| argenx SE | -417.15 Million EUR | 97.097% |
| BioSenic S.A. | -7.04 Million EUR | -72.017% |
| Celyad Oncology SA | -8.45 Million EUR | -43.195% |
| DBV Technologies S.A. | -85.24 Million EUR | 85.794% |
| Galapagos NV | -88.26 Million EUR | 86.28% |
| Genfit S.A. | -26.58 Million EUR | 54.439% |
| GeNeuro SA | -14.35 Million EUR | 15.653% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 24.279% |
| Innate Pharma S.A. | -12.66 Million EUR | 4.412% |
| Inventiva S.A. | -102.7 Million EUR | 88.209% |
| MaaT Pharma SA | -19.94 Million EUR | 39.277% |
| MedinCell S.A. | -20.97 Million EUR | 42.27% |
| Nanobiotix S.A. | -26.77 Million EUR | 54.778% |
| Onward Medical N.V. | -35.46 Million EUR | 65.852% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -166.201% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 47.316% |
| Pharming Group N.V. | -4.87 Million EUR | -148.179% |
| Poxel S.A. | -28.76 Million EUR | 57.899% |
| GenSight Biologics S.A. | -29.69 Million EUR | 59.22% |
| Transgene SA | -30.01 Million EUR | 59.649% |
| Financière de Tubize SA | -2.14 Million EUR | -464.839% |
| UCB SA | 604 Million EUR | 102.005% |
| Valneva SE | -82.08 Million EUR | 85.247% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 58.005% |